Call for papers - Reproduction, Technology and Society, a new section in Reproductive BioMedicine Online
Page URL: https://www.bionews.org.uk/page_90865

Organ transplants from pigs within a decade?

10 November 2008
Appeared in BioNews 483

New organs from 'designer pigs' could be ready to use in humans within a decade. The hope is to transplant the organs into humans who require them to help solve the problem of the shortage of transplant organs.

Lord Robert Winston, the fertility expert from Imperial College London, is one of the directors of Atazoa, the spin-out company that is pioneering the work on the pigs with a team at the California Institute of Technology, Pasadena, led by Dr Carol Readhead. He is attempting to genetically modify and breed special kinds of 'mini-pigs', which are about a quarter of the size of normal farm pigs and whose organs are the right size for humans.

The male pigs are injected with a cocktail of genes that alter their sperm, and genes are taken up in the offspring after they mate with normal sows. If the correct genes are taken up, the porcine organs will be modified to have human proteins on them, in an attempt to prevent rejection by the human body due to the immune system recognising and rejecting 'foreign bodies' on the pig organ. The hope is that once the donor pig has been created, a limitless and cheap supply of organs will be produced. Lord Winston has already successfully incorporated a test gene into the sperm of six pigs.

There are currently 8000 people on the waiting list for transplants in the UK, 7000 of who are waiting for a kidney. There are only enough donors for 3000 transplants per year. Lord Winston says: 'there is a massive shortage. Essentially, if you are waiting for a transplant, you are waiting for someone to die in a car accident'.

Pigs are considered ideal for 'xenotransplantation' (animal-to-human transplants) due to the similarities in their physiological make-up to humans, and they have many of the same diseases. Patients who receive the pig organs, however, will still have to take powerful immunosuppressant drugs for the rest of their lives, although no more than patients who receive human organs. Other benefits of the breeding of these pigs include biomedical research into understanding human diseases, and testing new medicines in the pigs to avoid risks to humans in late phase clinical trials.

Lord Winston aims to breed the first pigs next year, and hopes that transplantable organs could be ready within two to three years for testing and licensing. He says there have been problems with the progress of the project, however, due to 'red tape' that bans his team from mating and producing offspring from the transgenic pigs. The research might have to be moved to the US, where the regulations are more relaxed.

There has been some opposition to the research, for example from the campaign group People for the Ethical Treatment of Animals. It maintains that the 'obstacles to success in this research are colossal, the risk to humans incalculable and the cost in animal suffering is enormous'.

SOURCES & REFERENCES
Designer pigs with hearts genetically modified to help transplant patients 'could be here within a decade'
The Daily Mail |  7 November 2008
Organ transplants from pigs could be a reality in less than an decade, claims Lord Winston
The Daily Telegraph |  6 November 2008
Pig organs 'available to patients in a decade'
The Times |  7 November 2008
Transplant pigs 'will cost £3 million'
The Press Association |  7 November 2008
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
2 November 2015 - by Anna Smajdor and Guy Hardwick 
The new gene-editing technique CRISPR/Cas9 could remove one of the toughest barriers to the transplantation of pig organs to humans. And it has been suggested that the production of genetically modified (GM) pig organs could end the anguish of those waiting for suitable donors. But is it really a panacea?
10 October 2011 - by George Frodsham 
Scientists have found a new method of suppressing the automatic rejection of donated kidneys in transplant patients, by using the donor's stem cells. In a small trial carried out at Stanford University, California, eight out of 12 patients were able to stop taking anti-rejection drugs, which are usually a lifelong necessity, following this treatment....
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.